Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
The European Commission (EC) has approved an expanded label for Keytruda (pembrolizumab) as monotherapy for adults and children aged three years and older with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option. 17 March 2021
Biotechnology
German contract development and manufacturing company ProBioGen has signed a commercial multi-product license agreement with French pharma major Sanofi. 17 March 2021
Biotechnology
Positive results from a trial of Eli Lilly’s monoclonal antibody mirikizumab raise the prospect of further competition in the gastrointestinal disorder space. 17 March 2021
Biotechnology
French microbiome company MaaT Pharma has announced top-line results from a Phase II trial evaluating MaaT013 in a high-risk patient population with grade III-IV steroid-refractory, gastrointestinal-predominant acute graft-versus-host disease (SR-GI-aGvHD). 17 March 2021
Biotechnology
UK-based Vaccitech said today it has raised $168 million in a Series B financing. This includes $43 million in convertible loan notes previously issued by Vaccitech that converted into Series B shares. 17 March 2021
Biotechnology
In a filing with the US Securities and Exchange Commission (SEC), bluebird bio has announced the departure of its chief medical officer, David Davidson. 17 March 2021
Biotechnology
The regenerative medicine and advanced therapies sector raised a record $19.9 billion in funding in 2020, fueling the broader biotech sector and driving a rapidly advancing pipeline of potentially transformative therapies, according to the Alliance for Regenerative Medicine’s (ARM) 2020 Annual Report released today. 16 March 2021
Biotechnology
Nabriva Therapeutics has published a post-hoc analysis of data from the Phase III LEAP 2 study of oral antibiotic Xenleta (lefamulin). 16 March 2021
Biotechnology
Switzerland-based Genevant Sciences has entered into a global collaboration and license agreement with Japan’s largest drugmaker Takeda Pharmaceutical for the discovery, development and commercialization of LNP-delivered nucleic acid therapeutics directed to previously inaccessible drug targets in hepatic stellate cells to treat liver fibrosis. 16 March 2021
Biotechnology
As of lunchtime on Tuesday, 11 European countries had halted the rollout of COVID-19 Vaccine AstraZeneca after a number of cases of blood clots. 16 March 2021
Biotechnology
Canadian biopharma company and UK pharma major GlaxoSmithKline have started Phase III clinical testing of Medicago’s plant-derived COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, as part of the ongoing Phase II/III study. 16 March 2021
Biotechnology
Perception Neuroscience, a platform company of German biotech atai Life Sciences and Japan’s Otsuka have signed a collaboration and licensing agreement for the development and commercialization of Perception’s lead molecule, PCN-101 (arketamine) in Japan as a potential treatment for mood disorders such as major depressive disorder (MDD) and treatment-resistant depression (TRD). 16 March 2021
Biotechnology
Shares of AstraZeneca were up more than 3% at £72.11 in early trading today, after it revealed it has modified an existing agreement with the US government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody (LAAB) combination which is in late-stage development for the prevention and treatment of COVID-19. 16 March 2021
Biotechnology
Russian biotech firm Biocad has confirmed it will begin clinical trials of its anti-cancer drug Forteka (prolgolimab) in China, with the aim of its possible production in that country, according to local media reports. 15 March 2021
Biotechnology
Cell and gene therapy incubator ElevateBio has raised $525 million in a Series C financing. 15 March 2021
Biotechnology
Swiss pharma giant Novartis has announced new data that reinforces the transformational benefit of Zolgensma (onasemnogene abeparvovec), a one-time gene therapy treatment for spinal muscular atrophy (SMA). 15 March 2021
Biotechnology
Shares of US cancer specialist AVEO Oncology were down 1.85% at $12.21 in early trading today, after revealing it will regain its rights to AV-203 outside of North America, its clinical-stage potent humanized IgG1 monoclonal antibody that targets ErbB3 (also known as HER3), following the voluntary termination of its collaboration and license agreement by China-based CANbridge Life Sciences. 15 March 2021
Biotechnology
UK-based Clinigen Group has signed a distribution agreement with Amgen to supply part of its product portfolio to multiple countries across Africa and Asia. 15 March 2021
Biotechnology
A new study led by researchers from The University of Texas MD Anderson Cancer Center has shed some light on the matter of predicting when immunotherapies will work in cancer. 15 March 2021
Biotechnology
Gilead Sciences and pharma giant Merck & Cohave entered into an agreement to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir. 15 March 2021
All news
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
Biotechnology
Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was trading 83% lower at midday on Thursday. 25 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab mafodotin in combinations with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]) for multiple myeloma patients who have received at least one prior line of therapy. 25 November 2024
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $135 million Series B financing round. 25 November 2024
Biotechnology
StemCyte, a subsidiary of StemCyte International, has secured approval from the US Food and Drug Administration for Regenecyte, a cord blood-derived stem cell therapy. 25 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze